ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time-Highest Rates of Use Now in Triple-Negative and HER2+ Disease

Brittany L Murphy^{1

2}, Judy C Boughey³

Affiliations

¹ Department of Surgery, Mayo Clinic, Rochester, MN, USA.
² The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
³ Department of Surgery, Mayo Clinic, Rochester, MN, USA. boughey.judy@mayo.edu.

Comment

Brittany L Murphy et al. Ann Surg Oncol. 2018 Dec.

. 2018 Dec;25(Suppl 3):695-696.

doi: 10.1245/s10434-018-7046-9. Epub 2018 Nov 21.

Brittany L Murphy^{1

2}, Judy C Boughey³

¹ Department of Surgery, Mayo Clinic, Rochester, MN, USA.
² The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
³ Department of Surgery, Mayo Clinic, Rochester, MN, USA. boughey.judy@mayo.edu.

No abstract available

Comment on

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Murphy BL, et al. Ann Surg Oncol. 2018 Aug;25(8):2241-2248. doi: 10.1245/s10434-018-6531-5. Epub 2018 May 21. Ann Surg Oncol. 2018. PMID: 29786125